TLR9 and neoplasm: At a serum dilution of 1∶1600, RT+TLR9 agonist induced a significant level of tumor-reactive antibody, as compared with untreated (n = 8, p<0.05) and TLR9 agonist alone cohorts (n = 8, p<0.05).